Agile Therapeutics, Inc.
AGRX · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $19,593 | $10,884 | $4,101 | $749 |
| % Growth | 80% | 165.4% | 447.5% | – |
| Cost of Goods Sold | $8,978 | $6,836 | $10,718 | $282 |
| Gross Profit | $10,615 | $4,048 | -$6,617 | $467 |
| % Margin | 54.2% | 37.2% | -161.4% | 62.3% |
| R&D Expenses | $2,225 | $3,253 | $6,246 | $13,500 |
| G&A Expenses | $10,505 | $11,860 | $14,698 | $12,735 |
| SG&A Expenses | $28,274 | $42,229 | $58,142 | $36,020 |
| Sales & Mktg Exp. | $17,769 | $30,369 | $43,444 | $23,285 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $30,499 | $45,482 | $64,388 | $49,520 |
| Operating Income | -$19,884 | -$41,434 | -$71,005 | -$49,053 |
| % Margin | -101.5% | -380.7% | -1,731.4% | -6,549.1% |
| Other Income/Exp. Net | $5,419 | $11,347 | -$62 | -$2,800 |
| Pre-Tax Income | -$14,465 | -$30,087 | -$74,894 | -$51,853 |
| Tax Expense | $0 | -$4,675 | $1,691 | $0 |
| Net Income | -$14,465 | -$25,412 | -$76,585 | -$54,686 |
| % Margin | -73.8% | -233.5% | -1,867.5% | -7,301.2% |
| EPS | -6.71 | -58.79 | -63,115.49 | -1,291.56 |
| % Growth | 88.6% | 99.9% | -4,786.8% | – |
| EPS Diluted | -6.71 | -58.79 | -63,115.49 | -1,291.56 |
| Weighted Avg Shares Out | 2,157 | 432 | 1 | 42 |
| Weighted Avg Shares Out Dil | 2,157 | 432 | 1 | 42 |
| Supplemental Information | – | – | – | – |
| Interest Income | $78 | $80 | $25 | $309 |
| Interest Expense | $1,419 | $3,131 | $3,914 | $3,109 |
| Depreciation & Amortization | $386 | $1,534 | $2,223 | $276 |
| EBITDA | -$12,660 | -$25,422 | -$64,930 | -$48,468 |
| % Margin | -64.6% | -233.6% | -1,583.3% | -6,471% |